Interleukin-33 plasma levels in patients with relapsing-remitting multiple sclerosis. 2017

Fereshteh Alsahebfosoul, and Ilnaz Rahimmanesh, and Mansour Shajarian, and Masoud Etemadifar, and Nahid Sedaghat, and Zahra Hejazi, and Shamsi Naderi
Isfahan Research Center of Multiple Sclerosis, Isfahan, Iran.

Cytokines are implicated in the immunopathogenesis of multiple sclerosis (MS). Interleukin (IL)-33, one of the recently discovered members of the IL-1 superfamily, is a dual functional cytokine involved in various autoimmune disorders. In a case-control study, venous blood was collected from healthy subjects categorized as control group (n=44) and MS patients (n=44). All recruited patients were clinically diagnosed with relapsing-remitting MS (RRMS), including patients without treatment (new identified cases, n=16) and those treated with interferon beta (IFN-β) (n=28). The plasma levels of IL-33 in subjects were measured with ELISA. Significantly elevated IL-33 plasma levels were observed in RRMS patients (p=0.005). Furthermore, IFN-β-treated MS patients had lower levels of IL-33 compared to the untreated patients (p<0.001). Increased IL-33 plasma levels in the patient group might be associated with development of MS. These results could contribute to our better understanding about the role of IL-33 in the immunopathogenesis of MS.

UI MeSH Term Description Entries
D008297 Male Males
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000067596 Interleukin-33 A member of the INTERLEUKIN-1 protein family involved in the maturation of TH2 CELLS and the activation of MAST CELLS; BASOPHILS; EOSINOPHILS and NK CELLS. It is also produced by ENDOTHELIAL CELLS; EPITHELIAL CELLS and FIBROBLASTS; where it can function as an alarmin to modulate immune and inflammatory responses to tissue damage. IL-33,IL33,Interleukin 33
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D016899 Interferon-beta One of the type I interferons produced by fibroblasts in response to stimulation by live or inactivated virus or by double-stranded RNA. It is a cytokine with antiviral, antiproliferative, and immunomodulating activity. Interferon, Fibroblast,beta-Interferon,Fiblaferon,Interferon, beta,Interferon, beta-1,Interferon-beta1,beta-1 Interferon,Fibroblast Interferon,Interferon beta,Interferon beta1,Interferon, beta 1,beta 1 Interferon,beta Interferon
D020529 Multiple Sclerosis, Relapsing-Remitting The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914) Multiple Sclerosis, Acute Relapsing,Relapsing-Remitting Multiple Sclerosis,Acute Relapsing Multiple Sclerosis,Remitting-Relapsing Multiple Sclerosis,Multiple Sclerosis, Relapsing Remitting,Multiple Sclerosis, Remitting-Relapsing,Relapsing Remitting Multiple Sclerosis,Remitting Relapsing Multiple Sclerosis

Related Publications

Fereshteh Alsahebfosoul, and Ilnaz Rahimmanesh, and Mansour Shajarian, and Masoud Etemadifar, and Nahid Sedaghat, and Zahra Hejazi, and Shamsi Naderi
July 2021, Clinical neurology and neurosurgery,
Fereshteh Alsahebfosoul, and Ilnaz Rahimmanesh, and Mansour Shajarian, and Masoud Etemadifar, and Nahid Sedaghat, and Zahra Hejazi, and Shamsi Naderi
April 1992, Annals of the New York Academy of Sciences,
Fereshteh Alsahebfosoul, and Ilnaz Rahimmanesh, and Mansour Shajarian, and Masoud Etemadifar, and Nahid Sedaghat, and Zahra Hejazi, and Shamsi Naderi
June 2004, Acta neurologica Scandinavica,
Fereshteh Alsahebfosoul, and Ilnaz Rahimmanesh, and Mansour Shajarian, and Masoud Etemadifar, and Nahid Sedaghat, and Zahra Hejazi, and Shamsi Naderi
July 2017, Journal of the neurological sciences,
Fereshteh Alsahebfosoul, and Ilnaz Rahimmanesh, and Mansour Shajarian, and Masoud Etemadifar, and Nahid Sedaghat, and Zahra Hejazi, and Shamsi Naderi
July 2021, International journal of clinical practice,
Fereshteh Alsahebfosoul, and Ilnaz Rahimmanesh, and Mansour Shajarian, and Masoud Etemadifar, and Nahid Sedaghat, and Zahra Hejazi, and Shamsi Naderi
April 2015, Immunology letters,
Fereshteh Alsahebfosoul, and Ilnaz Rahimmanesh, and Mansour Shajarian, and Masoud Etemadifar, and Nahid Sedaghat, and Zahra Hejazi, and Shamsi Naderi
January 2016, Current pharmaceutical design,
Fereshteh Alsahebfosoul, and Ilnaz Rahimmanesh, and Mansour Shajarian, and Masoud Etemadifar, and Nahid Sedaghat, and Zahra Hejazi, and Shamsi Naderi
March 1990, Archives of neurology,
Fereshteh Alsahebfosoul, and Ilnaz Rahimmanesh, and Mansour Shajarian, and Masoud Etemadifar, and Nahid Sedaghat, and Zahra Hejazi, and Shamsi Naderi
May 2021, Brain and nerve = Shinkei kenkyu no shinpo,
Fereshteh Alsahebfosoul, and Ilnaz Rahimmanesh, and Mansour Shajarian, and Masoud Etemadifar, and Nahid Sedaghat, and Zahra Hejazi, and Shamsi Naderi
June 2003, Annals of neurology,
Copied contents to your clipboard!